Latest Cachexia Stories
NEW YORK, May 29, 2013 /PRNewswire/ -- Ohr Pharmaceutical (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that Dr. Irach Taraporewala, CEO, will present a corporate overview and business update at the second annual Marcum MicroCap Conference on Thursday, May 30, 2013 at 11:00 am ET. The Conference is being held at the Grand Hyatt Hotel in New York City. Details of the presentation are as...
NEW YORK, May 22, 2013 /PRNewswire/ -- Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for unmet medical needs, today announced the appointment of June S. Almenoff, M.D., Ph.D., to its Board of Directors. Dr. Almenoff has extensive experience in the pharmaceutical industry, working on early and late stage drug development. "We are delighted to have Dr. Almenoff join Ohr's Board," said Dr. Irach Taraporewala, CEO of Ohr...
Trial Results to be Submitted For U.S. Marketing Approval Under FDA Fast Track Designation For Promising New Therapies AUSTIN, Texas, Apr. 24, 2013 /PRNewswire/ -- XBiotech announced today enrollment of the first patient into its Phase III trial of Xilonix. The Pivotal study is designed to improve health and survival of late stage colorectal cancer patients with associated cachexia. The patient was enrolled by Dr. Eric Roeland at UC San Diego's Moores Cancer Center. The study is...
Company Fully Funded Through Completion of Phase II Squalamine Eye Drop Trial for Wet-AMD and Into 2015 NEW YORK, April 22, 2013 /PRNewswire/ -- Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for unmet medical needs, today announced that Ohr raised approximately $5.05 million dollars from institutional and accredited shareholders through the exercise of Series B Warrants. The Company intends to use the net proceeds...
Demonstrates Weight Maintenance and Increase in Patient Appetite and Quality Of Life NEW YORK, March 21, 2013 /PRNewswire/ -- Ohr Pharmaceutical (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced the results of a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia. Cancer cachexia is the complex, multi-symptom syndrome seen in late-stage cancer patients,...
NEW YORK, Feb. 7, 2013 /PRNewswire/ -- Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, announced today that Dr. Irach Taraporewala, Chief Executive Officer of Ohr Pharmaceutical, will be presenting at the 15(th) Annual BIO CEO and Investor 2013 conference, taking place at the Waldorf Astoria Hotel in New York City on February 11-12, 2013. Dr. Taraporewala's presentation will include an...
LUGANO, Switzerland and MEXICO CITY, January 29, 2013 /PRNewswire/ -- Swiss pharmaceutical Helsinn Group has granted Latin American specialty company Stendhal exclusive commercialization rights for Mexico, Venezuela, Colombia, Peru, Ecuador and most of Central American countries, to this novel ghrelin receptor agonist. Anamorelin is a new first-in-class, once daily drug being developed for the treatment of cachexia-anorexia in NSCLC, a serious multifactorial...
AUSTIN, Texas, Jan. 3, 2013 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced today that the company has been granted Fast Track designation by the FDA for its therapeutic monoclonal antibody MABp1 (CV-18C3) as a treatment to reduce the need for re-intervention after superficial femoral artery (SFA) revascularization. Strong positive results from a recent Phase II study demonstrated that treatment with MABp1 resulted in prolonged patency of the SFA and...
NEW YORK, Jan. 3, 2013 /PRNewswire/ -- Ohr Pharmaceutical (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, announced today that Dr. Irach Taraporewala, Chief Executive Officer of Ohr Pharmaceutical, will be presenting at the Biotech Showcase 2013 conference, taking place at The Parc 55 Hotel in San Francisco on January 7-9, 2013. Dr. Taraporewala's presentation will include an overview of Ohr's clinical...
NEW YORK, Dec. 27, 2012 /PRNewswire/ -- Ohr Pharmaceutical Inc., a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets, announced today that it has published a letter to shareholders, available on the Company's website, from its Chief Executive officer, Dr. Irach B. Taraporewala, Ph.D. The letter states: Dear Shareholder, I would like to take this opportunity to share the progress we have made in...
